Paclitaxel: A review of adverse toxicities and novel delivery strategies

Neena I. Marupudi, James E. Han, Khan W. Li, Violette M. Renard, Betty M. Tyler, Henry Brem

Research output: Contribution to journalReview articlepeer-review

247 Scopus citations


Better known as Taxol® (Bristol-Myers Squibb), paclitaxel is the first member of the taxane family to be used in cancer chemotherapy. The taxanes exert their cytotoxic effect by arresting mitosis through microtubule stabilization, resulting in cellular apoptosis. The use of paclitaxel as a chemotherapeutic agent has become a broadly accepted option in the treatment of patients with ovarian, breast and non-small cell lung cancers, malignant brain tumors, and a variety of other solid tumors. However, significant toxicities, such as myelo-suppression and peripheral neuropathy, limit the effectiveness of paclitaxel-based treatment regimens. This review addresses the toxicities associated with paclitaxel treatment and describes existing and future strategies of paclitaxel administration directed at limiting these toxicities.

Original languageEnglish (US)
Pages (from-to)609-621
Number of pages13
JournalExpert Opinion on Drug Safety
Issue number5
StatePublished - Sep 2007


  • Adverse effects
  • Cancer
  • Paclitaxel
  • Safety
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Paclitaxel: A review of adverse toxicities and novel delivery strategies'. Together they form a unique fingerprint.

Cite this